AstraZeneca Teams with Broad on Antibacterial, Antiviral Drug Research | GenomeWeb

NEW YORK (GenomeWeb News) – AstraZeneca and the Broad Institute today said they will collaborate on identifying new compounds that target bacterial and viral infections.

The alliance will employ Broad's expertise in bacterial genomics and biochemistry with its chemical library of 100,000 customized molecules known as Diversity-Oriented Synthesis compounds. The library is "designed to contain molecular shapes and structures not found anywhere else that can hit even the most challenging biological targets," the partners said in a joint statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.